A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies	B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Waldenstrom macroglobulinemia, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, tumor lysis syndrome, vascular disorder, vascular hemostatic disease	Recruiting	Phase 1	2026-07-31		NCT06708897

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Lomond Therapeutics Holdings, Inc.	3

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Norton Cancer Institute, St. Matthews Campus	Louisville	United States	9
The Ohio State University	Columbus	United States	191
University of Cincinnati	Cincinnati	United States	24
University of North Carolina at Chapel Hill	Chapel Hill	United States	129
UT Southwestern Medical Center	Dallas	United States	210